Impact Partnership Wealth LLC Makes New $70,000 Investment in Verve Therapeutics, Inc. (NASDAQ:VERV)

Impact Partnership Wealth LLC acquired a new position in Verve Therapeutics, Inc. (NASDAQ:VERV) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 12,466 shares of the company’s stock, valued at approximately $70,000.

A number of other institutional investors have also added to or reduced their stakes in the company. State Street Corp raised its holdings in Verve Therapeutics by 27.0% in the third quarter. State Street Corp now owns 4,253,217 shares of the company’s stock worth $20,586,000 after purchasing an additional 903,809 shares in the last quarter. Novo Holdings A S raised its holdings in Verve Therapeutics by 20.0% in the second quarter. Novo Holdings A S now owns 2,400,000 shares of the company’s stock worth $11,712,000 after purchasing an additional 400,000 shares in the last quarter. Geode Capital Management LLC raised its holdings in Verve Therapeutics by 2.6% in the third quarter. Geode Capital Management LLC now owns 1,600,687 shares of the company’s stock worth $7,749,000 after purchasing an additional 40,915 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in Verve Therapeutics by 72.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,559,393 shares of the company’s stock worth $7,547,000 after purchasing an additional 653,578 shares in the last quarter. Finally, FMR LLC raised its holdings in Verve Therapeutics by 0.3% in the third quarter. FMR LLC now owns 1,418,993 shares of the company’s stock worth $6,868,000 after purchasing an additional 3,873 shares in the last quarter. Institutional investors own 97.11% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Canaccord Genuity Group raised their price target on Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. HC Wainwright reduced their price target on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Finally, Royal Bank of Canada reduced their price target on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th.

Verve Therapeutics Price Performance

Verve Therapeutics stock opened at $7.91 on Friday. Verve Therapeutics, Inc. has a one year low of $4.30 and a one year high of $19.34. The stock has a market capitalization of $669.66 million, a PE ratio of -3.22 and a beta of 1.68. The business’s fifty day moving average is $5.96 and its 200 day moving average is $5.82.

Verve Therapeutics (NASDAQ:VERV) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.11. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The company had revenue of $6.87 million for the quarter, compared to analysts’ expectations of $2.75 million. During the same period last year, the firm posted ($0.72) earnings per share. Verve Therapeutics’s revenue was up 120.2% compared to the same quarter last year. As a group, sell-side analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.